Bhavik J. Pandya, PharmD^1*, Cynthia Z. Qi, MBA^2*, Hongbo Yang, PhD^2*, Andy Garnham, MSc^1*, Manasee V. Shah, MPH^1* and Amer M. Zeidan, MBBS, MHS³

¹Astellas Pharma Global Development, Inc., Northbrook, IL
²Analysis Group Inc., Boston, MA
³Yale University School of Medicine, New Haven, CT

Gail J. Roboz, MD¹, Hartmut Döhner², Christopher Pocock, MBBS³, Hervé Dombret, MD^4,5, Farhad Ravandi, MBBS⁶, Jun Ho Jang, MD, PhD⁷, Dominik Selleslag, MD⁸, Jiří Mayer⁹, Uwe M. Martens, MD¹⁰, Jane L. Liesveld, MD¹¹, Teresa Bernal del Castillo, MD, PhD^12*, Ming-Chung Wang, MD^13*, Ignazia La Torre^14*, Barry Skikne, MD^15,16*, Keshava Kumar, PhD^16*, Qian Dong, DrPH^16*, Julia Braverman, PhD^16*, Salem Abi Nehme, PhD^16*, C.L. Beach, PharmD^16* and Andrew H Wei, MBBS, PhD^17,18

¹Weill Medical College of Cornell University New York-Presbyterian Hospital, New York, NY
²Ulm University Hospital, Ulm, Germany
³Kent & Canterbury Hospital, Canterbury, United Kingdom
⁴Institut de Recherche Saint Louis, Université de Paris, Paris, France
⁵Hôpital Saint-Louis, Assistance Publique – Hôpitaux de Paris (AP-HP), Paris, France
⁶Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁷Department of Hematology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
⁸AZ Sint-Jan Brugge-Oostende AV, Bruges, Belgium
⁹University Hospital Brno, Brno, Czech Republic
¹⁰Clinics Heilbronn, MOLIT Institute for Personalized Medicine, Heilbronn, Germany
¹¹The James P Wilmot Cancer Institute, University of Rochester, Rochester, NY
¹²Hospital Universitario Central Asturias, Oviedo, Spain
¹³Division of Hematology/Oncology, Chang Gung Memorial Hospital Kaohsiung, Kaohsiung, Taiwan
¹⁴Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland
¹⁵Kansas University Medical Center, Kansas City, KS
¹⁶Bristol Myers Squibb, Princeton, NJ
¹⁷The Alfred Hospital, Melbourne, Australia
¹⁸Australian Centre for Blood Diseases, Monash University, Melbourne, Australia

William A. Wood, MD, MPH¹, Donna S. Neuberg, ScD², John Colton Thompson^3*, Martin S. Tallman, MD ⁴, Mikkael A. Sekeres, MD, MS⁵, Laurie H. Sehn, MD, MPH⁶, Kenneth Anderson, MD⁷, Aaron D Goldberg, MD, PhD⁸, Nathan A Pennell, MD, PhD^9*, Charlotte M. Niemeyer, MD¹⁰, Emily Tucker, MS^11*, Kathleen Hewitt, DNP, CPHQ, AACC, RN^12*, Robert M Plovnick, MD, MS¹² and Lisa K. Hicks, MD, MSc¹³

¹Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, NC
²Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
³ASH Research Collaborative, Washington, DC
⁴Memorial Sloan-Kettering Cancer Center, New York, NY
⁵Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁶BC Cancer Centre for Lymphoid Cancer, University of British Columbia, vancouver, BC, Canada
⁷Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁸Department of Medicine, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY
⁹Lung Program, Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
¹⁰University Children's Hospital, Freiburg, Germany
¹¹ASH Research Collaborative, Washington DC, DC
¹²American Society of Hematology, Washington DC, DC
¹³Division of Hematology/Oncology, St. Michael's Hospital, Toronto, ON, Canada

Ehab L. Atallah, MD¹, Rodrigo Maegawa, MD^2*, Dominick Latremouille-Viau, MSc^3*, Carmine Rossi, PhD^3*, Annie Guerin, MSc^3* and Pallavi Patwardhan, PhD^2*

¹Medical College of Wisconsin, Wauwatosa, WI
²Novartis Pharmaceuticals Corporation, East Hanover, NJ
³Analysis Group, Inc., Montreal, QC, Canada

Ivy Abraham, MD¹, Garth Rauscher, PhD, MPH^2*, Anand Ashwin Patel, MD³, William B Pearse, MD⁴, Priya Rajakumar, MD^5*, Stephanie Berg, DO⁶, Ahmed Aleem, MD^6*, Ami Dave, MD^5*, Sushma Bharadwaj, MD^7*, Koosha Paydary, MD^7*, Maria Acevedo-Mendez¹, Richard Gomez^6*, Kylie Carlson^6*, Stephanie B. Tsai, MD, MS⁶, Jessica K. Altman, MD⁴, Wendy Stock, MD³, John G. Quigley¹, Maryam Zia, MD^7*, Melissa L. Larson, MD⁵ and Irum Khan, MD⁸

¹Division of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL
²Division of Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, IL
³Department of Medicine, Section of Hematology-Oncology, University of Chicago, Chicago, IL
⁴Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
⁵Division of Hematology, Oncology and Stem Cell Transplant, Rush University Medical Center, Chicago, IL
⁶Division of Hematology and Oncology, Loyola University Medical Center, Maywood, IL
⁷Division of Hematology and Oncology, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL
⁸Division of Hematology and Oncology, University of Illinois, Chicago, IL

Pamela C Egan, MD^1,2, Emmanuelle Belanger, PhD^3*, Orestis A. Panagiotou, MD, PhD^4*, Vinay B Rao^5*, Aryeh Pelcovits, MD⁵, Thomas W. LeBlanc, MD, MA, MS⁶ and Adam J Olszewski, MD⁴

¹Alpert Medical School of Brown University, Providence, RI
²Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI
³Center for Gerontology and Health Care Research, Brown University School of Public Health, Providence, RI
⁴Brown University, Providence, RI
⁵Warren Alpert Medical School of Brown University, Providence, RI
⁶Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Hillsborough, NC